ArticleBiomaterials research2026
Photocrosslinkable Chitosan Quaternary Ammonium Salt-Based Ternary Hydrogel with Fibroblast Growth Factor 21 for Diabetic Wound Healing.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds represent a critical public health challenge due to impaired healing processes driven by chronic inflammation, infection, and biomechanical deficiencies. Despite advances in wound dressings and negative-pressure therapy, current treatments often fail to provide sufficient mechanical support or to fully resolve inflammatory responses, resulting in prolonged ulceration and high risk of complications. To address these limitations, a photocrosslinkable chitosan quaternary ammonium salt (CQS) derivative (methacrylated CQS [CQS-MA]) was developed to accelerate gelation and improve structural integrity. We then used ultraviolet-initiated copolymerization of CQS-MA with gelatin methacrylate (GelMA) and type I collagen to fabricate a ternary composite hydrogel encapsulating fibroblast growth factor 21 (FGF-21), termed G/C-CS@FGF-21. This composite hydrogel synergistically combined FGF-21's early-stage inflammation-resolving activity, CQS's sustained antimicrobial function, GelMA's tunable mechanical resilience, and collagen's native cell-adhesive ligands, which could promote all phases of wound repair. In vitro, G/C-CS@FGF-21 promoted macrophage polarization toward the anti-inflammatory M2 phenotype and enhanced fibroblast proliferation and migration. In a full-thickness diabetic mouse wound-healing model, treatment with G/C-CS@FGF-21 accelerated wound closure by mitigating inflammation and promoting reepithelialization and angiogenesis. These findings suggest that the G/C-CS@FGF-21 hydrogel holds strong potential for future clinical translation in diabetic wound management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.